Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma / chronic lymphocytic leukemia…
The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…
Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. Although angiogenesis inhibitors, including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai /…
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…
The implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing…
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (…
The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies…
Since 2015, ten new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon,…
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. The…
MARKET OUTLOOK Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…